Australian Clinical Labs (ASX: ACL) Lifts Margin and Sets FY27 Guidance

Major Australian private pathology provider, Australian Clinical Labs, increased underlying earnings and widened its margin in fiscal 2026, despite lower revenue and subdued pathology demand. It also issued fiscal 2027 guidance pointing to modest revenue growth and a broadly stable margin range.

Earnings Improve as Revenue Slips

Revenue fell 0.7% to $735.8 million for the year ended June 30. ACL attributed the decline to weak market growth, Medicare funding cuts and continued optimisation of its collection-centre network.

However, underlying earnings before interest and tax rose 1.7% to $69.2 million. The underlying EBIT margin expanded 20 basis points to 9.4%.

Underlying net profit increased 4.3% to $35.5 million. Underlying earnings per share climbed 8.5% to 18.3 cents, reflecting higher profitability and the share buyback.

The result shows ACL generated more underlying profit from a smaller revenue base. Labour efficiencies, procurement savings and revenue initiatives offset inflation and regulated wage increases.

Laboratory efficiency, measured by panels per full-time employee, improved 10.4%. Labour costs represented 43.5% of revenue, despite wage pressures and the lower top line.

Statutory Profit Tells a Different Story

Statutory net profit fell 26.8% to $24 million. Statutory EBIT declined 16.1% to $55.5 million.

The reported result included $6.2 million of costs relating to the Medlab settlement with the Australian Information Commissioner. It also included prior-period labour costs and other legal and redundancy expenses.

Free cash flow before interest, tax and financing was $64.7 million. That figure excludes the one-off $6.2 million settlement payment and was 8.7% below fiscal 2025.

ACL returned $47.1 million through dividends and buybacks during the year. This included $25.3 million of dividends and $21.8 million spent repurchasing shares.

Dividend and Balance Sheet

The board declared a fully franked final dividend of 9.25 cents per share. This takes the full-year dividend to 13 cents per share, representing 69% of underlying net profit.

The dividend has a September 3 record date and will be paid on September 23. Net debt, excluding lease liabilities, stood at $37.4 million at year-end.

Gearing was 0.51 times underlying cash EBITDA before AASB 16. ACL said its banking facilities remain within covenants, with refinancing targeted by December 31, 2026.

FY27 Range and Wage Risk

ACL expects fiscal 2027 revenue between $745 million and $765 million. Underlying EBIT is forecast between $67 million and $73 million, implying a margin of 9% to 9.5%.

The guidance incorporates a 4.75% wage increase linked to Modern Awards. ACL plans to counter higher costs through billing changes, price increases, automation and workforce alignment.

However, guidance excludes the final gender-undervaluation wage adjustment for pathology collectors. That adjustment will be updated on January 1, 2027, with its impact communicated later.

Incoming Chief Executive Officer Greg Horan said: “The market environment remains challenging, but ACL has clear levers within its control and a platform built to deliver long-term sustainable value.”

The on-market buyback is expected to continue, subject to funding requirements, strategic investments and ongoing capital expenditure.

About Australian Clinical Labs

Australian Clinical Labs provides pathology testing through NATA-accredited laboratories across Australia. It serves doctors, specialists, patients, hospitals and corporate clients. The company is also one of the country’s largest private hospital pathology businesses. Its operating model combines medical and scientific expertise with technology to support clinical decision-making and improve patient care.